TrialThe Lancet. Oncology2018

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.

Giuseppe Giaccone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.